Clinton Astle
Long-time research associate of David Harrison at The Jackson Laboratory, with work on mouse blood stem cells and aging since the 1970s, and a co-author of the Interventions Testing Program papers that showed rapamycin extends mouse lifespan
The Jackson Laboratory, Bar Harbor, Maine (papers with David E. Harrison, 1976–2019)
Clinton Astle is a co-author of five Atlas papers from the Interventions Testing Program (ITP) of the US National Institute on Aging. The ITP tests drugs and supplements for effects on lifespan in genetically mixed mice, running the same experiment at three sites (The Jackson Laboratory, the University of Michigan and UT Health San Antonio) so that a result has to hold up in all three. The 2009 Nature paper (HAR2009) showed that rapamycin, a drug that blocks mTOR, extended lifespan even when started late in life at about 600 days of age. Later papers showed that the gain depends on dose and is larger in females (MIL2011, MIL2014), that acarbose and 17-alpha-estradiol extend life mainly in males (HAR2014), and that resveratrol, green tea extract, curcumin and several other popular compounds did not change lifespan (STR2012). Publishing negative results was part of the programme's design. All of this is mouse work.
Astle has worked with David Harrison at The Jackson Laboratory in Bar Harbor, Maine, for decades. Their first joint PubMed paper, on immune-cell responses in mice, dates from 1976, and PubMed lists more than 50 papers by the two together. Their most recent joint paper in PubMed, from 2019, reported that adding glycine to the diet modestly extended lifespan in ITP mice. On that paper the name appears in full as C Michael Astle, at The Jackson Laboratory.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2009 | A | Rapamycin fed late in life extends lifespan in genetically heterogeneous mice HAR2009 Co-author of the Nature paper showing that rapamycin fed late in life extends lifespan in genetically mixed mice. |
| 2011 | A | Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice MIL2011 Co-author of the ITP paper in which rapamycin extended lifespan but resveratrol and simvastatin did not. |
| 2012 | A | Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice STR2012 Co-author of the ITP paper that found no lifespan effect from resveratrol, green tea extract, curcumin, oxaloacetic acid or medium-chain triglyceride oil. |
| 2014 | A | Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. HAR2014 Co-author of the ITP paper in which acarbose, 17-alpha-estradiol and NDGA extended lifespan, mainly in males. |
| 2014 | A | Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction MIL2014 Co-author of the ITP paper showing that rapamycin's lifespan effect depends on dose and sex. |
Co-authors in the Atlas 9
People with a profile here who share at least one study with Clinton Astle.
ShowHide
- David E. Harrison 5 shared studies Led the Jackson Laboratory site of the NIA Interventions Testing Program. His 2009 Nature paper showed that rapamycin extends the lifespan of genetically diverse mice even when feeding starts at 20 months of age, which the authors described as the first pharmacological extension of lifespan in both sexes of a mammal
- Nancy L. Nadon 5 shared studies Scientist and programme official at the US National Institute on Aging who oversaw research resources for aging biology and helped run the Interventions Testing Program that found rapamycin extends mouse lifespan
- Randy Strong 5 shared studies Leads the San Antonio site of the NIA Interventions Testing Program, which tests each compound in parallel at three sites under one shared protocol. He first-authored the program's reports on resveratrol and other supplements (2012) and on rapamycin combined with acarbose (2022)
- Richard A. Miller 5 shared studies Leads the University of Michigan site of the NIA Interventions Testing Program. His papers showed that rapamycin extends mouse lifespan when started in middle age, and that the size of the benefit depends on dose and differs between males and females
- Kevin Flurkey 4 shared studies Biologist of aging at The Jackson Laboratory who has studied mouse lifespan and hormones since the early 1980s and co-authored the Interventions Testing Program papers on rapamycin
- Zelton Dave Sharp 3 shared studies Molecular biologist at UT Health San Antonio who works on rapamycin and aging in mice, from the Interventions Testing Program lifespan studies to cancer prevention in tumour-prone mice
- Adam B. Salmon Biologist of aging at UT Health San Antonio whose work in this Atlas spans rapamycin in mice and in common marmosets. He is a co-author on the Interventions Testing Program reports from the San Antonio site and on the marmoset rapamycin studies on blood markers, epigenetic age and the salivary gland
- David A. Sinclair Geneticist of aging at Harvard Medical School, known for work on sirtuins, NAD+ and the idea that aging stems from a loss of epigenetic information, who appears in this Atlas as a co-author on two mouse lifespan studies
- James L. Kirkland Founder of the field of senolytics, drugs that clear senescent cells, and a leader of clinical trials of ageing-targeted therapies
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.